180 results about "Intestinal inflammation" patented technology

The invention discloses an enteritis patient condition severity risk early warning method, a medium and equipment. The method comprises the following steps: acquiring a borborygmus original signal and a clinical multi-dimensional physiological parameter sequence through a sensing device; constructing a borborygmus dynamic characteristic spectrum based on the borborygmus original signal to generate an acoustic biomarker time sequence; inputting the acoustic biomarker time sequence and the clinical multi-dimensional physiological parameter sequence into a multi-modal fusion early warning model to obtain an intestinal inflammation risk index; executing a signal quality self-evaluation process and generating a data quality warning code when the signal quality is abnormal; triggering a multi-node collaborative monitoring mechanism based on the risk index to generate an intestinal state multi-dimensional situation map; establishing an individualized risk baseline and generating a graded early warning instruction; and finally outputting a comprehensive early warning report. According to the method, multi-modal fusion analysis of the borborygmus signal and the clinical parameters is realized, the accuracy and timeliness of illness state early warning are remarkably improved through dynamic risk assessment and signal quality monitoring, and a reliable basis is provided for clinical decision making.

The invention relates to the technical field of functional food and biological medicine, in particular to a modified pseudo-ginseng exosome and an intestinal conditioning gel composition and application thereof. According to the gel beverage, an exosome derived from panax notoginseng callus cultured in a laboratory is used as a core active component, is modified through phosphatidylserine-aminated pectin-genipin and is embedded into a hydrogel matrix composed of carboxymethyl chitosan and sodium alginate, so that the exosome is protected from being degraded in the stomach, and the activity of the exosome in the stomach is improved. The exosome can be effectively released under the intestinal pH and flora environment, so that the targeted delivery of the intestinal tract is realized, and the preparation method is suitable for improving the intestinal inflammation and maintaining the intestinal health. The invention can effectively solve the technical problems of uncontrollable raw material quality and safety, low oral delivery stability and active ingredient availability and poor medication compliance of the existing plant exosome.

The invention discloses a personalized diet recommendation method for enteritis patients, a medium and equipment. The method comprises the following steps: continuously collecting diet image data, physiological state time sequence data and subjective symptom feedback data; performing food material component deconstruction and cooking mode identification on the diet image through a convolutional neural network, and generating a structured diet vector; analyzing physiological state time sequence data by using a hidden Markov model, and constructing an individualized physiological rhythm map; establishing a symptom triggering condition probability matrix based on a multi-modal association mining algorithm; generating an exploratory diet scheme according to the real-time physiological state of the user and the conditional probability matrix; dynamically updating the conditional probability matrix through an online reinforcement learning mechanism; and finally, periodically outputting a personalized diet taboo list and a safety exploration list. According to the method, through the dynamic correlation analysis of fusing the time sequence physiological features and the dietary components, accurate matching of diet recommendation and individual intestinal tract state fluctuation is realized, and the individuation and adaptability of diet intervention are effectively improved.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention discloses a lactobacillus mucus fermentation strain. The microbial preservation number of the lactobacillus mucus fermentation strain is CCTCC (China Center for Type Culture Collection) NO: M 20252262. The strain can inhibit enterotoxigenic escherichia coli, and can treat or slow down diarrhea, intestinal oxidative damage, intestinal inflammation damage, intestinal morphological damage, intestinal barrier function damage and intestinal flora disorder caused by the enterotoxigenic escherichia coli. The strain is a probiotic with a clinical application prospect.

The invention relates to the technical field of microorganisms, and particularly discloses bifidobacterium longum LFS01 and application thereof. The bifidobacterium longum LFS01 is preserved in the China General Microbiological Culture Collection Center on July 9, 2025, the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.35159, and the bifidobacterium longum LFS01 is classified and named as the bifidobacterium longum LFS01. The bifidobacterium longum LFS01 provided by the invention can be specifically and efficiently colonized in an intestinal tract after gut cleaning, proliferation of pathogenic bacteria is inhibited through competitive rejection, an intestinal barrier is repaired in a multi-target manner, intestinal inflammation can be effectively relieved, a flora structure can be improved, mucous membrane integrity can be recovered, and the intestinal tract can be effectively protected. A safe and effective biological prevention and treatment strategy is provided for solving the problems of flora disorder and pathogenic bacterium infection caused by gut purging.

The invention discloses a full-life-cycle health management method for enteritis patients, a medium and equipment, and the method comprises the steps: extracting a key lever factor through a lever point recognition algorithm based on obtained full-life-cycle health data, and generating a lever point intervention priority sequence; generating an individualized toughness development path plan in combination with a calculation result of the toughness evaluation model, and designing a structured self-verification experiment scheme according to the individualized toughness development path plan; continuously updating the leverage point recognition algorithm and the toughness evaluation model by using an adaptive learning algorithm according to a scheme execution result until the optimal parameter configuration and the individualized health management strategy are locked; and when the sorting stability of the key lever factors exceeds the standard, starting a grading response mechanism to generate a precise intervention scheme, and finally outputting a full-life-cycle health management comprehensive scheme. According to the method, a dynamic optimization closed loop is constructed, so that a management strategy is converted from static matching to dynamic self-adaption, and the defects of an existing method in the aspects of intervention target spot recognition, adaptive capacity quantification and strategy continuous optimization are overcome.

The application discloses a feed additive for improving intestinal health of animals and preventing and treating intestinal diseases and application thereof, and relates to the technical field of green and healthy breeding. The application firstly confirms that indole-3-butyric acid (IBA) has no toxic effect on cells and can relieve oxidative stress damage and inflammation damage of the cells in an effective concentration. Meanwhile, the application also fills the application blank of IBA as one of indole derivatives in livestock production, and provides experimental basis and theoretical basis for the fact that IBA is expected to be a new green additive for replacing antibiotics and zinc oxide. More importantly, the application also finds that IBA has positive effects in aspects of resisting diarrhea, repairing intestinal barrier damage, relieving intestinal inflammation and preventing and treating intestinal related diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to a multifunctional peptide and application thereof in anti-inflammatory, antibacterial, mucous membrane repair and intestinal secretion promotion. Specifically, the invention designs a polypeptide and an analogue which have guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucous membrane repair functions at the same time. The polypeptide can be combined with GUCY2C, stimulate generation of cyclic guanosine monophosphate (cGMP) in cells, promote intestinal fluid secretion, inhibit release of proinflammatory factors, relieve inflammatory response, promote repair of intestinal injury mucosa, inhibit growth of opportunistic pathogenic bacteria and accelerate intestinal homeostasis recovery after intestinal preparation. The composition can effectively promote intestinal tract cleaning, does not cause intestinal inflammation and mucosal lesion, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

The application provides a copper selenide-halloysite-mannose composite drug delivery system, which comprises a carrier, the carrier is halloysite nanotubes (HNTs), copper selenide nanoparticles (CuSe) are in situ grown on the tube wall of the halloysite nanotubes to form a composite CuSe@HNTs; and mannose is loaded in the lumen of the CuSe@HNTs to form a composite drug delivery system CuSe@HNTs@ME. The application also provides a preparation method and application of the copper selenide-halloysite-mannose composite drug delivery system. The drug delivery system can maintain stability in a gastric acid environment, directly reaches an intestinal inflammation site through an oral route, and significantly reduces intestinal inflammation symptoms.

The invention discloses a copper ion-kaempferol nano-composite and application thereof in treatment of inflammatory bowel disease, the obtained nano-composite has very strong stability and active oxygen scavenging ability, and has excellent oxidation resistance and anti-inflammatory ability, and the specific performance is as follows: the surface is negatively charged, and the nano-composite can specifically target the diseased region of intestinal inflammation, so that the copper ion-kaempferol nano-composite can be applied to treatment of inflammatory bowel disease. The intestinal mucosal barrier injury is effectively repaired, the imbalance state of intestinal flora is adjusted, and the intestinal inflammation microenvironment is remarkably improved; the antioxidant and anti-inflammatory capacities of cells can be enhanced by regulating and controlling a PI3K-Akt signal channel and a nuclear factor kappa B (NF-kappa B) signal channel; the compound shows an excellent treatment effect in mouse models of typical inflammatory bowel diseases such as ulcerative colitis and Crohn's disease and related complications of bowel diseases. The invention provides a new way for constructing a multi-target and multi-layer treatment platform for the inflammatory bowel disease of a natural product.

This invention belongs to the field of vertebrate technology, specifically relating to a method for constructing a complex inflammatory animal model in middle-aged and elderly individuals and its related applications. The method includes: selecting adult animals for adaptive feeding, daily subcutaneous injection of D-galactose to establish a susceptibility to aging and oxidative stress, and administering sodium dextran sulfate (DSS) solution within a specific time window to induce intestinal inflammation, forming a complex inflammatory state through gut-hepatic axis interactions. The constructed animal model simultaneously exhibits intestinal inflammatory damage, abnormal hepatic oxidative stress, and aging-related characteristics, realistically simulating the pathological process of gut-hepatic axis dysfunction in middle-aged and elderly individuals. This model is suitable for screening and evaluating drugs, medical nutrition products, and functional foods that improve gut-hepatic axis dysfunction, providing a reliable technical platform for research on related disease mechanisms and the development of interventional substances.

The invention discloses application of rosmarinic acid in preparation of a medicine or health food for preventing and treating hyperuricemia of a patient with renal insufficiency. The medicine for preventing and treating hyperuricemia of the patient with renal insufficiency is an XOD inhibitor or an ABCG2 gene expression promoter. The rosmarinic acid can significantly reduce the serum uric acid level of HUA mice induced by high purine diet, promote ABCG2-mediated intestinal uric acid excretion, and relieve HUA-induced intestinal inflammation and barrier injury by adjusting intestinal flora. The rosmarinic acid is safe and free of toxic and side effects, and has very important application prospects.

A pharmaceutical composition includes a combination of a guanylate cyclase C (GUCY2C) agonist and a short-chain C2 to C5 fatty acid and / or a salt and / or a prodrug thereof in a therapeutically effective amount and one or more pharmaceutically acceptable excipients as well as to a method of preventing and / or treating colorectal tumorigenesis and / or carcinogenesis and / or chronic intestinal inflammation and / or cystic fibrosis related gastrointestinal manifestations by administering to a patient, who has developed or is at risk to develop colorectal tumorigenesis and / or carcinogenesis and / or chronic intestinal inflammation and / or cystic fibrosis related gastrointestinal manifestations, a therapeutically effective amount of a combination of a GUCY2C agonist and a short-chain C2 to C5 fatty acid or a salt or a prodrug thereof.

The invention discloses an application of a P4HA1 inhibitor in preparation of a medicine for treating congenital megacolon-related enterocolitis, deeply clarifies an immune metabolic axis of 'P4HA1-hydroxyproline-eIF5A-IRF4-IL17', and discloses a new mechanism that metabolite hydroxyproline regulates the activity of eIF5A and promotes nuclear translocation of IRF4 so as to enhance TH17 cell mediated inflammatory response. Therefore, a brand new perspective is provided for understanding metabolic immune regulation of intestinal inflammation. By using the P4HA1 inhibitor (such as 1, 4-DPCA), secretion of IL-17 can be effectively inhibited, intestinal inflammation injury of HAEC model mice can be remarkably relieved, and a clear pharmacodynamic basis is achieved.

The present application relates to the field of microorganisms, in particular to a mucinophilic Akkermansia strain and application thereof, the mucinophilic Akkermansia has a preservation number of CCTCC NO: M 20241304.The mucinophilic Akkermansia AKK-86 of the present application has good effects of promoting iron absorption, improving iron metabolism, and relieving intestinal inflammation.In addition, the mucinophilic Akkermansia of the present application can also promote the production of GLP-1, and has potential application in reducing blood sugar and weight loss products.

The invention discloses a recombinant clostridium praeparatum fpPRPS protein, the amino acid sequence of the recombinant protein is shown as SED ID No.3, and the nucleotide sequence of a gene for coding the recombinant protein is shown as SED ID No.2. The invention further discloses a preparation method of the recombinant clostridium praeparatum fpPRPS protein. Experiments prove that the recombinant clostridium praeparatum fpPRPS protein prepared by the invention has effective anti-inflammatory and anti-tumor components, and is simple to prepare, good in activity, high in purity, low in toxicity and easy to popularize and apply clinically and commercially; the invention has important significance for effectively treating and relieving intestinal inflammation and occurrence of various tumors including intestinal tumors and treating various Th17-related inflammations or tumors.

The present application provides a nutritional composition for improving intestinal inflammation and microbial imbalance and application thereof. Specifically, the present application provides application of a composition in preparation of a product for improving intestinal inflammation and / or microbial imbalance, wherein the composition comprises 2'-fucosyllactose and lacto-N-neotetraose, and the mass ratio of 2'-fucosyllactose to lacto-N-neotetraose is (1-5.5):1. The present application also provides a food containing the composition, and application of the composition or the food in preparation of a product for improving intestinal inflammation and microbial imbalance.

The application discloses application of a natural oyster zinc peptide product in preparation of a medicine for preventing and treating enteritis. The application verifies the function of the natural oyster zinc peptide product in preventing and treating enteritis through animal experiments, the natural oyster zinc peptide product can improve the apparent symptoms of ulcerative colitis of mice caused by DSS by regulating the oxidation stress level, relieving the inflammatory reaction, maintaining the intestinal barrier and reducing the cell apoptosis, and the natural oyster zinc peptide product can also regulate the intestinal flora and metabolic products of the intestinal flora of the enteritis mice, so that the intestinal inflammation is relieved. The natural oyster zinc peptide product used in the application has good safety, compared with common anti-inflammatory and immunity-enhancing medicines, the natural oyster zinc peptide product has lower cost and no side effect, and the effect of relieving enteritis is remarkable. Therefore, the natural oyster zinc peptide product has a good prospect in development of medicines for preventing and treating enteritis.

This invention discloses the application of berberine-loaded herbal carbon dots in the preparation of drugs for treating ulcerative colitis. The BLCDs of this invention exert their therapeutic effect through a dual synergistic mechanism: directly scavenging reactive oxygen species through surface oxygen-containing functional groups, and simultaneously inhibiting the NLRP3 inflammatory pathway and downstream pro-inflammatory factors by promoting IL-10 expression. In a DSS-induced ulcerative colitis mouse model, BLCDs showed superior efficacy compared to the positive control drug 5-ASA and its single component, significantly improving intestinal inflammation, oxidative stress, and barrier dysfunction. Their therapeutic advantage stems from the intestinal retention effect conferred by their larger particle size, as well as their regulatory effects on intestinal flora and metabolites, particularly by inhibiting Klebsiella to reduce TMAO production, thereby activating the multi-cascade regulatory network of IL-10.

The invention discloses an ROS (reactive oxygen species) response type oral microgel-in-situ intestinal biological adhesion patch system. The patch system is prepared from the following raw materials: a polymer framework material, an ROS breakable crosslinking component, a covalent adhesion component, a negative electricity targeting component, an initiation system and a solvent, the ROS breakable crosslinking group is selected from monomers with double bonds at the two ends and an oxidative fracture bond in the middle; the covalent adhesion component is selected from monomers simultaneously containing double bonds and an X group, and the X group is selected from one or more of an N-hydroxysuccinimide group, an isocyanate group, an epoxy group and an aldehyde group; the negative electricity targeting component is selected from a monomer containing carboxyl. The system disclosed by the invention has the advantages that (1) oral administration can be realized; (2) the structure of the inflammation part is changed under the triggering of active oxygen; (3) converting the dispersed microgel into an integral bioadhesive patch in situ; (4) mucous membrane barrier reconstruction, ROS (reactive oxygen species) removal and local drug sustained release functions are realized; and (5) the composition can be stably retained at intestinal inflammation parts for not less than 24 hours.

The application discloses application of pinoresinol diglucoside in increasing short-chain fatty acids in the postmenopausal intestinal tract and relieving postmenopausal intestinal inflammation, and belongs to the medical field. The pinoresinol diglucoside can regulate the abundance of Akkermansia, another branch bacteria, parabacteroides, rumenococcus and other genera in the intestinal tract, promote the expression of short-chain fatty acids in the postmenopausal intestinal tract, and then relieve postmenopausal intestinal inflammation and osteoporosis. The application opens up a new clinical approach for the treatment of postmenopausal women and diseases related to intestinal flora disorder.

The invention discloses an inflammatory bowel disease treatment method based on intestinal flora regulatory gene CD24 expression. According to the method, expression or functions of CD24 in host intestinal epithelial cells are up-regulated, the intestinal flora structure is adjusted, and intestinal inflammation is relieved. CD24 up-regulation can be realized by transfecting a CD24 gene overexpression vector, applying a transcription factor or a small molecule agonist or enhancing the activity of an endogenous gene by utilizing a gene editing technology. The CD24 is regulated and controlled, so that the proportion of the phylum firmicalis to the phylum bacteroides can be normalized, the enrichment of short-chain fatty acid producing flora is promoted, the activation of NF-kappa B and NLRP3 inflammasomes is inhibited, and the intestinal barrier function is enhanced. The DSS induced colitis model is established by drinking a 2-5% dextran sodium sulfate solution by a mouse, and simulates the pathological characteristics of human ulcerative colitis. Intervention modes include oral administration, enema or nanoparticle targeted delivery of the CD24 agonist pharmaceutical composition. The invention provides a new strategy for the treatment of inflammatory bowel diseases, especially ulcerative colitis, and has obvious dual curative effects of anti-inflammation and flora regulation.

This invention discloses a naturally formed nutritional licking brick specifically for musk deer and its preparation method. Using calcium silicate as the skeleton material, it is compounded with yeast culture powder, bentonite, compound probiotics, sweeteners, and flavoring agents. The resulting licking brick continuously releases soluble nutrients and active bacteria during the musk deer's licking process. The specific combination of probiotics and yeast culture powder components effectively improves the intestinal immunity of captive musk deer, significantly reduces intestinal inflammation, and simultaneously lowers cortisol levels in feces, alleviating stress responses. Using yeast culture powder, calcium silicate, and bentonite as a composite coagulant, the licking brick prepared by mold casting exhibits optimal moisture resistance during storage. Furthermore, the licking brick has a smooth appearance, a compact and sturdy structure, excellent molding performance, and retains its structural integrity even after immersion in water, making it suitable for preparing products related to improving the intestinal health and immunity of musk deer.

The invention discloses mucoprotein nano-selenium gas motor hydrogel as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method of the mucoprotein nano-selenium gas motor hydrogel comprises the following steps: adding a carbonyl compound and selenite into an emulsifier solution, and adding a reducing agent for mixing reaction to obtain a nano-selenium gas motor, oxidized mucoprotein and the nano-selenium gas motor are mixed, then a cross-linking agent is added, the oxidized mucoprotein is subjected to a cross-linking reaction to form gel, and the mucoprotein nano-selenium gas motor hydrogel is obtained. The mucoprotein nano-selenium gas motor hydrogel is constructed by wrapping a gas motor into a mucoprotein hydrogel delivery system, the mucoprotein nano-selenium gas motor hydrogel can be specifically delivered to a colitis disease part through rectal administration, and meanwhile, the safe and controllable release and mucous membrane protection effects of the nano-selenium gas motor are realized; therefore, a new thought is provided for treating enteritis.

The application discloses a kind of low morbidity feed for California bass antibiotic-free breeding and preparation method thereof, belong to aquatic feed field.The feed is composed of 60~80 parts of basic feed component, 10~20 parts of fermented plant protein, 2~6 parts of functional compound additives.Fermented plant protein is prepared by compound fermentation of butyric acid clostridium and bacillus subtilis from soybean meal, bran, rice bran, brown sugar and the like.Functional compound additives include pre-embedded material and microcapsule coated sodium butyrate, and the pre-embedded material is prepared by embedding treatment of astaxanthin, lutein and rosemary extract with β-cyclodextrin and gum arabic.The application significantly reduces the incidence of intestinal inflammation of California bass through the synergistic effect of fermented plant protein, pre-embedded antioxidant combination and microcapsule sodium butyrate, enhances antioxidant capacity, improves body color, improves the stability of active ingredients and feeding rate, and realizes low morbidity under antibiotic-free breeding conditions.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

The invention discloses an application of an AC13 compound or a pharmaceutical salt thereof in preparation of a medicine for treating enteritis. The structure of the AC13 compound is shown in the specification. The AC13 compound disclosed by the invention has a remarkable treatment effect on enteritis as a small molecule compound, and has the characteristics of low toxicity and remarkable curative effect. Therefore, the AC13 compound can be used as a lead compound of the major disease enteritis, has important development prospects and clinical application values, and also provides a scientific basis for further exploring the enteritis pathogenesis mechanism.

The invention relates to the technical field of biological medicines, and discloses a dual-targeting adhesion-immune activation fusion peptide, an anti-escherichia coli O157: H7 monoclonal antibody GS2-D3, curcumin nanoparticles and a probiotic composition composed of the curcumin nanoparticles. The fusion peptide solves structural conflicts by inserting an alpha helix stable domain composed of four EAAAK repetitive units and a GPGP flexible buffer domain, a targeting domain YIGSR and an MUC2 binding domain PTPSFTT are introduced to improve the targeting efficiency, and the enzymolysis resistance is enhanced through site mutation; the monoclonal antibody GS2-D3 can be used for specifically recognizing escherichia coli O157: H7; the curcumin nanoparticles improve the stability and bioavailability of curcumin. The probiotic composition contains the components, has the effects of efficient colonization, bacteriostasis, inflammation resistance and intestinal flora regulation, can effectively treat intestinal inflammation, is low in cost and high in safety, and has good clinical transformation potential.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ackermania muciniphila and recombinant trichina serine protease carried by a derivative of the ackermania muciniphila to preparation of a medicine for treating intestinal inflammation symptoms. According to the present invention, the ackermann muciniphila and the ackermann muciniphila derivative carrying recombinant trichina serine are firstly disclosed, such that the physical barrier of the intestinal mucosa is repaired through the synergistic effect, the expression of TNF-alpha, IL-6, IL-1beta and other proinflammatory factors is specifically regulated and inhibited, the intestinal flora structure is remodeled, and the intestinal inflammation state is significantly improved; experimental results show that the Ackerman muciniphila and the derivative thereof carrying the recombinant trichina serine protease can significantly relieve weight loss of mice with intestinal inflammation induced by DSS, reduce DAI score, and reverse the phenomena of shortened colon and abnormal swelling of spleen. According to the invention, the probiotics and the parasite-derived protein are combined, so that the method has the advantages of high efficiency, safety and easiness in large-scale production, and a new biological preparation strategy is provided for accurate treatment of IBD.